Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Mar;17(3):301–307. doi: 10.1111/j.1365-2125.1984.tb02345.x

Acute effects of ketanserin on left ventricular function, metabolism and coronary blood flow.

J M Walker, P T Wilmshurst, S M Juul, D J Coltart
PMCID: PMC1463376  PMID: 6712862

Abstract

An acute intravenous bolus of 10 mg ketanserin (a specific 5-HT antagonist) caused an abrupt fall in left ventricular systolic pressure of 17 +/- 9.2 mm Hg (P less than 0.025) in ten patients undergoing cardiac catheterisation for chest pains. A fall in pulmonary artery diastolic pressure of 2.1 +/- 0.74 mm Hg (P less than 0.02) was also observed. No changes in resting heart rate occurred and the response to pacing was largely unmodified by ketanserin, except for a reduction in pulmonary vascular resistance (3.70 +/- 1.27 units to 2.97 +/- 1.44 units, P less than 0.05), at the fastest rate (136 +/- 3 beats/min). At the highest pacing rate coronary sinus blood flow fell (83 +/- 12 ml 100 g-1 min-1 to 68 +/- 8 ml 100 g-1 min-1, P less than 0.05), as did myocardial oxygen consumption (18 +/- 2 ml-1 min to 14 +/- 1 ml min-1, P less than 0.05) after the drug. No changes in the parameters of left ventricular contractile function could be attributed to ketanserin, save for a modest increase in the ejection fraction (48 +/- 6% to 57 +/- 6%, P less than 0.05) in seven patients. There were no alterations in myocardial metabolism of lactate, pyruvate, hydroxybutyrate, glycerol nor free fatty acids after ketanserin. The findings are consistent with a peripheral site of action of this drug and its blood pressure lowering effect in the subjects suggest a non-specific hypotensive action rather than an anti-hypertensive effect.

Full text

PDF
301

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bulkley B. H., Klacsmann P. G., Hutchins G. M. Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinicopathologic study of 9 patients with progressive systemic sclerosis. Am Heart J. 1978 May;95(5):563–569. doi: 10.1016/0002-8703(78)90297-1. [DOI] [PubMed] [Google Scholar]
  2. Carruthers M., Young D. A. Free fatty acid estimation by a semi-automated fluorimetric method. Clin Chim Acta. 1973 Dec 27;49(3):341–348. doi: 10.1016/0009-8981(73)90231-3. [DOI] [PubMed] [Google Scholar]
  3. De Cree J., Verhaegen H., Symoens J. Acute blood-pressure-lowering effect of ketanserin. Lancet. 1981 May 23;1(8230):1161–1162. doi: 10.1016/s0140-6736(81)92331-x. [DOI] [PubMed] [Google Scholar]
  4. Demoulin J. C., Bertholet M., Soumagne D., David J. L., Kulbertus H. E. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study. Lancet. 1981 May 30;1(8231):1186–1188. doi: 10.1016/s0140-6736(81)92352-7. [DOI] [PubMed] [Google Scholar]
  5. Ganz W., Tamura K., Marcus H. S., Donoso R., Yoshida S., Swan H. J. Measurement of coronary sinus blood flow by continuous thermodilution in man. Circulation. 1971 Aug;44(2):181–195. doi: 10.1161/01.cir.44.2.181. [DOI] [PubMed] [Google Scholar]
  6. Guazzi M. D., Polese A., Bartorelli A., Loaldi A., Fiorentini C. Evidence of a shared mechanism of vasoconstriction in pulmonary and systemic circulation in hypertension: a possible role of intracellular calcium. Circulation. 1982 Oct;66(4):881–886. doi: 10.1161/01.cir.66.4.881. [DOI] [PubMed] [Google Scholar]
  7. HOHORST H. J., KREUTZ F. H., BUECHER T. [On the metabolite content and the metabolite concentration in the liver of the rat]. Biochem Z. 1959;332:18–46. [PubMed] [Google Scholar]
  8. Henry P. D., Yokoyama M. Supersensitivity of atherosclerotic rabbit aorta to ergonovine. Mediation by a serotonergic mechanism. J Clin Invest. 1980 Aug;66(2):306–313. doi: 10.1172/JCI109858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Leysen J. E., Awouters F., Kennis L., Laduron P. M., Vandenberk J., Janssen P. A. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981 Mar 2;28(9):1015–1022. doi: 10.1016/0024-3205(81)90747-5. [DOI] [PubMed] [Google Scholar]
  10. Maseri A., L'Abbate A., Baroldi G., Chierchia S., Marzilli M., Ballestra A. M., Severi S., Parodi O., Biagini A., Distante A. Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of "preinfarction" angina. N Engl J Med. 1978 Dec 7;299(23):1271–1277. doi: 10.1056/NEJM197812072992303. [DOI] [PubMed] [Google Scholar]
  11. Oliva P. B., Potts D. E., Pluss R. G. Coronary arterial spasm in Prinzmetal angina. Documentation by coronary arteriography. N Engl J Med. 1973 Apr 12;288(15):745–751. doi: 10.1056/NEJM197304122881501. [DOI] [PubMed] [Google Scholar]
  12. Steele P. P., Weily H. S., Davies H., Genton E. Platelet function studies in coronary artery disease. Circulation. 1973 Dec;48(6):1194–1200. doi: 10.1161/01.cir.48.6.1194. [DOI] [PubMed] [Google Scholar]
  13. Thompson D. S., Naqvi N., Juul S. M., Coltart D. J., Jenkins B. S., Webb-Peploe M. M. Haemodynamic and metabolic effects of atenolol in patients with angina pectoris. Br Heart J. 1980 Jun;43(6):668–679. doi: 10.1136/hrt.43.6.668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. WILLIAMSON D. H., MELLANBY J., KREBS H. A. Enzymic determination of D(-)-beta-hydroxybutyric acid and acetoacetic acid in blood. Biochem J. 1962 Jan;82:90–96. doi: 10.1042/bj0820090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wenting G. J., Man in 't Veld A. J., Woittiez A. J., Boomsma F., Schalekamp M. A. Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. Br Med J (Clin Res Ed) 1982 Feb 20;284(6315):537–539. doi: 10.1136/bmj.284.6315.537. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES